Cell-based interventions for neurologic conditions: Ethical challenges for early human trials

D. J H Mathews, J. Sugarman, H. Bok, D. M. Blass, J. T. Coyle, P. Duggan, J. Finkel, H. T. Greely, A. Hillis, A. Hoke, R. Johnson, M. Johnston, J. Kahn, D. Kerr, J. Kurtzberg, S. Matthew Liao, J. W. McDonald, G. McKhann, K. B. Nelson, M. RaoA. Regenberg, A. W. Siegel, K. Smith, D. Solter, H. Song, A. Vescovi, W. Young, J. D. Gearhart, R. Faden

Research output: Contribution to journalArticle

Abstract

Background: Attempts to translate basic stem cell research into treatments for neurologic diseases and injury are well under way. With a clinical trial for one such treatment approved and in progress in the United States, and additional proposals under review, we must begin to address the ethical issues raised by such early forays into human clinical trials for cell-based interventions for neurologic conditions. Methods: An interdisciplinary working group composed of experts in neuroscience, cell biology, bioethics, law, and transplantation, along with leading disease researchers, was convened twice over 2 years to identify and deliberate on the scientific and ethical issues raised by the transition from preclinical to clinical research of cell-based interventions for neurologic conditions. Results: While the relevant ethical issues are in many respects standard challenges of human subjects research, they are heightened in complexity by the novelty of the science, the focus on the CNS, and the political climate in which the science is proceeding. Conclusions: Distinctive challenges confronting US scientists, administrators, institutional review boards, stem cell research oversight committees, and others who will need to make decisions about work involving stem cells and their derivatives and evaluate the ethics of early human trials include evaluating the risks, safety, and benefits of these trials, determining and evaluating cell line provenance, and determining inclusion criteria, informed consent, and the ethics of conducting early human trials in the public spotlight. Further study and deliberation by stakeholders is required to move toward professional and institutional policies and practices governing this research.

Original languageEnglish (US)
Pages (from-to)288-293
Number of pages6
JournalNeurology
Volume71
Issue number4
DOIs
StatePublished - Jul 22 2008

Fingerprint

Ethics
Nervous System
Stem Cell Research
Institutional Practice
Research
Clinical Trials
Organizational Policy
Nervous System Trauma
Bioethics
Research Ethics Committees
Neurosciences
Nervous System Diseases
Administrative Personnel
Informed Consent
Cell Biology
Stem Cells
Transplantation
Research Personnel
Safety
Cell Line

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Mathews, D. J. H., Sugarman, J., Bok, H., Blass, D. M., Coyle, J. T., Duggan, P., ... Faden, R. (2008). Cell-based interventions for neurologic conditions: Ethical challenges for early human trials. Neurology, 71(4), 288-293. https://doi.org/10.1212/01.wnl.0000316436.13659.80

Cell-based interventions for neurologic conditions : Ethical challenges for early human trials. / Mathews, D. J H; Sugarman, J.; Bok, H.; Blass, D. M.; Coyle, J. T.; Duggan, P.; Finkel, J.; Greely, H. T.; Hillis, A.; Hoke, A.; Johnson, R.; Johnston, M.; Kahn, J.; Kerr, D.; Kurtzberg, J.; Liao, S. Matthew; McDonald, J. W.; McKhann, G.; Nelson, K. B.; Rao, M.; Regenberg, A.; Siegel, A. W.; Smith, K.; Solter, D.; Song, H.; Vescovi, A.; Young, W.; Gearhart, J. D.; Faden, R.

In: Neurology, Vol. 71, No. 4, 22.07.2008, p. 288-293.

Research output: Contribution to journalArticle

Mathews, DJH, Sugarman, J, Bok, H, Blass, DM, Coyle, JT, Duggan, P, Finkel, J, Greely, HT, Hillis, A, Hoke, A, Johnson, R, Johnston, M, Kahn, J, Kerr, D, Kurtzberg, J, Liao, SM, McDonald, JW, McKhann, G, Nelson, KB, Rao, M, Regenberg, A, Siegel, AW, Smith, K, Solter, D, Song, H, Vescovi, A, Young, W, Gearhart, JD & Faden, R 2008, 'Cell-based interventions for neurologic conditions: Ethical challenges for early human trials', Neurology, vol. 71, no. 4, pp. 288-293. https://doi.org/10.1212/01.wnl.0000316436.13659.80
Mathews, D. J H ; Sugarman, J. ; Bok, H. ; Blass, D. M. ; Coyle, J. T. ; Duggan, P. ; Finkel, J. ; Greely, H. T. ; Hillis, A. ; Hoke, A. ; Johnson, R. ; Johnston, M. ; Kahn, J. ; Kerr, D. ; Kurtzberg, J. ; Liao, S. Matthew ; McDonald, J. W. ; McKhann, G. ; Nelson, K. B. ; Rao, M. ; Regenberg, A. ; Siegel, A. W. ; Smith, K. ; Solter, D. ; Song, H. ; Vescovi, A. ; Young, W. ; Gearhart, J. D. ; Faden, R. / Cell-based interventions for neurologic conditions : Ethical challenges for early human trials. In: Neurology. 2008 ; Vol. 71, No. 4. pp. 288-293.
@article{6a2e3b6a66244cf798461458dcf60a96,
title = "Cell-based interventions for neurologic conditions: Ethical challenges for early human trials",
abstract = "Background: Attempts to translate basic stem cell research into treatments for neurologic diseases and injury are well under way. With a clinical trial for one such treatment approved and in progress in the United States, and additional proposals under review, we must begin to address the ethical issues raised by such early forays into human clinical trials for cell-based interventions for neurologic conditions. Methods: An interdisciplinary working group composed of experts in neuroscience, cell biology, bioethics, law, and transplantation, along with leading disease researchers, was convened twice over 2 years to identify and deliberate on the scientific and ethical issues raised by the transition from preclinical to clinical research of cell-based interventions for neurologic conditions. Results: While the relevant ethical issues are in many respects standard challenges of human subjects research, they are heightened in complexity by the novelty of the science, the focus on the CNS, and the political climate in which the science is proceeding. Conclusions: Distinctive challenges confronting US scientists, administrators, institutional review boards, stem cell research oversight committees, and others who will need to make decisions about work involving stem cells and their derivatives and evaluate the ethics of early human trials include evaluating the risks, safety, and benefits of these trials, determining and evaluating cell line provenance, and determining inclusion criteria, informed consent, and the ethics of conducting early human trials in the public spotlight. Further study and deliberation by stakeholders is required to move toward professional and institutional policies and practices governing this research.",
author = "Mathews, {D. J H} and J. Sugarman and H. Bok and Blass, {D. M.} and Coyle, {J. T.} and P. Duggan and J. Finkel and Greely, {H. T.} and A. Hillis and A. Hoke and R. Johnson and M. Johnston and J. Kahn and D. Kerr and J. Kurtzberg and Liao, {S. Matthew} and McDonald, {J. W.} and G. McKhann and Nelson, {K. B.} and M. Rao and A. Regenberg and Siegel, {A. W.} and K. Smith and D. Solter and H. Song and A. Vescovi and W. Young and Gearhart, {J. D.} and R. Faden",
year = "2008",
month = "7",
day = "22",
doi = "10.1212/01.wnl.0000316436.13659.80",
language = "English (US)",
volume = "71",
pages = "288--293",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Cell-based interventions for neurologic conditions

T2 - Ethical challenges for early human trials

AU - Mathews, D. J H

AU - Sugarman, J.

AU - Bok, H.

AU - Blass, D. M.

AU - Coyle, J. T.

AU - Duggan, P.

AU - Finkel, J.

AU - Greely, H. T.

AU - Hillis, A.

AU - Hoke, A.

AU - Johnson, R.

AU - Johnston, M.

AU - Kahn, J.

AU - Kerr, D.

AU - Kurtzberg, J.

AU - Liao, S. Matthew

AU - McDonald, J. W.

AU - McKhann, G.

AU - Nelson, K. B.

AU - Rao, M.

AU - Regenberg, A.

AU - Siegel, A. W.

AU - Smith, K.

AU - Solter, D.

AU - Song, H.

AU - Vescovi, A.

AU - Young, W.

AU - Gearhart, J. D.

AU - Faden, R.

PY - 2008/7/22

Y1 - 2008/7/22

N2 - Background: Attempts to translate basic stem cell research into treatments for neurologic diseases and injury are well under way. With a clinical trial for one such treatment approved and in progress in the United States, and additional proposals under review, we must begin to address the ethical issues raised by such early forays into human clinical trials for cell-based interventions for neurologic conditions. Methods: An interdisciplinary working group composed of experts in neuroscience, cell biology, bioethics, law, and transplantation, along with leading disease researchers, was convened twice over 2 years to identify and deliberate on the scientific and ethical issues raised by the transition from preclinical to clinical research of cell-based interventions for neurologic conditions. Results: While the relevant ethical issues are in many respects standard challenges of human subjects research, they are heightened in complexity by the novelty of the science, the focus on the CNS, and the political climate in which the science is proceeding. Conclusions: Distinctive challenges confronting US scientists, administrators, institutional review boards, stem cell research oversight committees, and others who will need to make decisions about work involving stem cells and their derivatives and evaluate the ethics of early human trials include evaluating the risks, safety, and benefits of these trials, determining and evaluating cell line provenance, and determining inclusion criteria, informed consent, and the ethics of conducting early human trials in the public spotlight. Further study and deliberation by stakeholders is required to move toward professional and institutional policies and practices governing this research.

AB - Background: Attempts to translate basic stem cell research into treatments for neurologic diseases and injury are well under way. With a clinical trial for one such treatment approved and in progress in the United States, and additional proposals under review, we must begin to address the ethical issues raised by such early forays into human clinical trials for cell-based interventions for neurologic conditions. Methods: An interdisciplinary working group composed of experts in neuroscience, cell biology, bioethics, law, and transplantation, along with leading disease researchers, was convened twice over 2 years to identify and deliberate on the scientific and ethical issues raised by the transition from preclinical to clinical research of cell-based interventions for neurologic conditions. Results: While the relevant ethical issues are in many respects standard challenges of human subjects research, they are heightened in complexity by the novelty of the science, the focus on the CNS, and the political climate in which the science is proceeding. Conclusions: Distinctive challenges confronting US scientists, administrators, institutional review boards, stem cell research oversight committees, and others who will need to make decisions about work involving stem cells and their derivatives and evaluate the ethics of early human trials include evaluating the risks, safety, and benefits of these trials, determining and evaluating cell line provenance, and determining inclusion criteria, informed consent, and the ethics of conducting early human trials in the public spotlight. Further study and deliberation by stakeholders is required to move toward professional and institutional policies and practices governing this research.

UR - http://www.scopus.com/inward/record.url?scp=50549094908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50549094908&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000316436.13659.80

DO - 10.1212/01.wnl.0000316436.13659.80

M3 - Article

C2 - 18463365

AN - SCOPUS:50549094908

VL - 71

SP - 288

EP - 293

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 4

ER -